The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer

The direct effect of TSH on bone metabolism in vivo is difficult to capture as the changes of its concentrations are followed by respective alterations of thyroid hormone levels. We evaluated the effect of recombinant human TSH (rhTSH) on sclerostin and other bone markers in 29 patients after total...

Full description

Bibliographic Details
Main Authors: Arkadiusz Zygmunt, Kinga Krawczyk-Rusiecka, Elżbieta Skowrońska-Jóźwiak, Katarzyna Wojciechowska-Durczyńska, Ewa Głowacka, Zbigniew Adamczewski, Andrzej Lewiński
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/10/21/4905
_version_ 1797512284309815296
author Arkadiusz Zygmunt
Kinga Krawczyk-Rusiecka
Elżbieta Skowrońska-Jóźwiak
Katarzyna Wojciechowska-Durczyńska
Ewa Głowacka
Zbigniew Adamczewski
Andrzej Lewiński
author_facet Arkadiusz Zygmunt
Kinga Krawczyk-Rusiecka
Elżbieta Skowrońska-Jóźwiak
Katarzyna Wojciechowska-Durczyńska
Ewa Głowacka
Zbigniew Adamczewski
Andrzej Lewiński
author_sort Arkadiusz Zygmunt
collection DOAJ
description The direct effect of TSH on bone metabolism in vivo is difficult to capture as the changes of its concentrations are followed by respective alterations of thyroid hormone levels. We evaluated the effect of recombinant human TSH (rhTSH) on sclerostin and other bone markers in 29 patients after total thyroidectomy for differentiated thyroid cancer (DTC), without any signs of disease recurrence, who received L-thyroxine, most at non-suppressive doses. For two consecutive days, the patients were administered a standard dose of 0.9 mg rhTSH, i.m. Concentrations of sclerostin, osteocalcin, β-CrossLaps, PTH, and some other parameters, were measured before and five days after the first rhTSH administration. The greater the increase in TSH concentration (∆TSH), the greater the decrease in: ∆sclerostin (r = −0.672; <i>p</i> < 0.001), ∆β-CrossLaps (r = −0.580; <i>p</i> < 0.001) and ∆osteocalcin (r = −0.405; <i>p</i> = 0.029) levels, were recorded. The degree of TSH increase depended on the baseline PTH (r = 0.651; <i>p</i> < 0.001), age, and creatinine concentrations. rhTSH strongly inhibited bone turnover, thus, TSH—independently of thyroid hormones—exerted a direct protective effect on bone metabolism. Baseline PTH affected the magnitude of TSH increase and the degree of lowering in sclerostin and β-CrossLaps that suggest factors affecting PTH may play a role in the effect of TSH on the bone.
first_indexed 2024-03-10T05:59:43Z
format Article
id doaj.art-5d4f77d22540431abe6dbcb240cd082c
institution Directory Open Access Journal
issn 2077-0383
language English
last_indexed 2024-03-10T05:59:43Z
publishDate 2021-10-01
publisher MDPI AG
record_format Article
series Journal of Clinical Medicine
spelling doaj.art-5d4f77d22540431abe6dbcb240cd082c2023-11-22T21:04:24ZengMDPI AGJournal of Clinical Medicine2077-03832021-10-011021490510.3390/jcm10214905The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid CancerArkadiusz Zygmunt0Kinga Krawczyk-Rusiecka1Elżbieta Skowrońska-Jóźwiak2Katarzyna Wojciechowska-Durczyńska3Ewa Głowacka4Zbigniew Adamczewski5Andrzej Lewiński6Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandDepartment of Laboratory Diagnostics, Research Institute, Polish Mother’s Memorial Hospital, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Research Institute, Polish Mother’s Memorial Hospital, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandThe direct effect of TSH on bone metabolism in vivo is difficult to capture as the changes of its concentrations are followed by respective alterations of thyroid hormone levels. We evaluated the effect of recombinant human TSH (rhTSH) on sclerostin and other bone markers in 29 patients after total thyroidectomy for differentiated thyroid cancer (DTC), without any signs of disease recurrence, who received L-thyroxine, most at non-suppressive doses. For two consecutive days, the patients were administered a standard dose of 0.9 mg rhTSH, i.m. Concentrations of sclerostin, osteocalcin, β-CrossLaps, PTH, and some other parameters, were measured before and five days after the first rhTSH administration. The greater the increase in TSH concentration (∆TSH), the greater the decrease in: ∆sclerostin (r = −0.672; <i>p</i> < 0.001), ∆β-CrossLaps (r = −0.580; <i>p</i> < 0.001) and ∆osteocalcin (r = −0.405; <i>p</i> = 0.029) levels, were recorded. The degree of TSH increase depended on the baseline PTH (r = 0.651; <i>p</i> < 0.001), age, and creatinine concentrations. rhTSH strongly inhibited bone turnover, thus, TSH—independently of thyroid hormones—exerted a direct protective effect on bone metabolism. Baseline PTH affected the magnitude of TSH increase and the degree of lowering in sclerostin and β-CrossLaps that suggest factors affecting PTH may play a role in the effect of TSH on the bone.https://www.mdpi.com/2077-0383/10/21/4905thyrotropinsclerostinparathormonbone turnover markers
spellingShingle Arkadiusz Zygmunt
Kinga Krawczyk-Rusiecka
Elżbieta Skowrońska-Jóźwiak
Katarzyna Wojciechowska-Durczyńska
Ewa Głowacka
Zbigniew Adamczewski
Andrzej Lewiński
The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
Journal of Clinical Medicine
thyrotropin
sclerostin
parathormon
bone turnover markers
title The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
title_full The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
title_fullStr The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
title_full_unstemmed The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
title_short The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
title_sort effect of recombinant human tsh on sclerostin and other selected bone markers in patients after total thyroidectomy for differentiated thyroid cancer
topic thyrotropin
sclerostin
parathormon
bone turnover markers
url https://www.mdpi.com/2077-0383/10/21/4905
work_keys_str_mv AT arkadiuszzygmunt theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT kingakrawczykrusiecka theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT elzbietaskowronskajozwiak theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT katarzynawojciechowskadurczynska theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT ewagłowacka theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT zbigniewadamczewski theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT andrzejlewinski theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT arkadiuszzygmunt effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT kingakrawczykrusiecka effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT elzbietaskowronskajozwiak effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT katarzynawojciechowskadurczynska effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT ewagłowacka effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT zbigniewadamczewski effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer
AT andrzejlewinski effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer